IMvigor011: A Phase 3 Trial of Circulating Tumour (ct)DNA-Guided Adjuvant Atezolizumab vs Placebo in Muscle-Invasive Bladder Cancer

Thomas Powles, MBBS, MRCP, MD discusses how, his study reports that in the phase 3 IMvigor011 trial, ctDNA-positive patients with muscle-invasive bladder cancer who received adjuvant atezolizumab had statistically significant improvements in both disease-free survival and overall survival compared with placebo. The results support using serial ctDNA monitoring to identify patients who benefit from immunotherapy while safely sparing persistently ctDNA-negative patients from unnecessary treatment.